• Reference Citation Analysis
  • v
  • v
  • Find an Article
Number Citation Analysis
1
Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.3086] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
2
Worry about ovarian cancer risk and use of screening by high-risk women: How you recruit affects what you find. ACTA ACUST UNITED AC 2004;129A:130-5. [PMID: 15316957 DOI: 10.1002/ajmg.a.30247] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA